Guardant Health (GH) PT Raised to $125 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts GH Hot Sheet
Price: $170.73 -4.51%
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Canaccord Genuity analyst Mark Massaro raised the price target on Guardant Health (NASDAQ: GH) to $125.00 (from $96.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alstom SA (ALO:FP) (ALSMY) PT Lowered to EUR13 at Deutsche Bank
- AP Moller Maersk (MAERSKB:DC) (AMKBY) PT Raised to DKK19,010 at Deutsche Bank
- Huhtamaki Oyj (HUH1V:FH) PT Lowered to EUR31 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
